EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening

Harry Wilders, George Biggs, Sam M. Rowe, Emma E. Cawood, Ioannis G. Riziotis, Alan R. Rendina, Emma K. Grant, Jonathan Pettinger, David J. Fallon, Mark Skehel, David House, Nicholas C. O. Tomkinson und 1 weitere

Angewandte Chemie · 03.02.2025 · 137 (6)

DOI: 10.1002/ange.202418314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie, online erschienen am 10.12.2024. Verfasst von Harry Wilders und 12 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council, Cancer Research UK, Medical Research Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reactive fragment (RF) screening has emerged as an efficient method for ligand discovery across the proteome, irrespective of a target's perceived tractability. To date, however, the efficiency of subsequent optimisation campaigns has largely been low‐throughput, constrained by the need for synthesis and purification of target compounds. We report an efficient platform for ‘direct‐to‐biology’ (D2B) screening of cysteine‐targeting chloroacetamide RFs, wherein synthesis is performed in 384‐well plates allowing direct assessment in downstream biological assays without purification. Here, the developed platform was used to optimise inhibitors of SARS‐CoV‐2 main protease (M Pro ), an established drug target for the treatment of COVID‐19. An initial RF hit was developed into a series of potent inhibitors, and further exploration using D2B screening enabled a ‘switch’ to a reversible inhibitor series. This example of ligand discovery for M Pro illustrates the acceleration that D2B chemistry can offer for optimising RFs towards covalent inhibitor candidates, as well as providing future impetus to explore the evolution of RFs into non‐covalent ligands.

Förderung

  • Engineering and Physical Sciences Research Council
  • Cancer Research UK
  • Medical Research Council
  • Wellcome Trust

Zitieren

APA

Wilders, H., Biggs, G., Rowe, S. M., Cawood, E. E., Riziotis, I. G., Rendina, A. R., Grant, E. K., Pettinger, J., Fallon, D. J., Skehel, M., House, D., Tomkinson, N. C. O., & Bush, J. T. (2025). Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening. Angewandte Chemie, 137(6). https://doi.org/10.1002/ange.202418314

Vancouver

Wilders H, Biggs G, Rowe SM, Cawood EE, Riziotis IG, Rendina AR, et al. Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening. Angewandte Chemie. 2025;137(6). doi:10.1002/ange.202418314

BibTeX
@article{Wilders2025,
  author = {Wilders, Harry and Biggs, George and Rowe, Sam M. and Cawood, Emma E. and Riziotis, Ioannis G. and Rendina, Alan R. and Grant, Emma K. and Pettinger, Jonathan and Fallon, David J. and Skehel, Mark and House, David and Tomkinson, Nicholas C. O. and Bush, Jacob T.},
  title = {Expedited SARS‐CoV‐2 Main Protease Inhibitor Discovery through Modular ‘Direct‐to‐Biology’ Screening},
  journal = {Angewandte Chemie},
  year = {2025},
  volume = {137},
  number = {6},
  doi = {10.1002/ange.202418314}
}
Kostenlos starten →